The ACTR1B Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A2780 ovarian cancer cell line. This product contains a heterogeneous pool of cells with targeted disruption of the ACTR1B gene, encoding a core dynactin subunit. The polyclonal format provides a population-level loss-of-function model for studying collective effects of ACTR1B ablation without clonal isolation, offering a renewable resource for dynactin research in an ovarian cancer context.
The A2780 host line originates from an endometrioid ovarian adenocarcinoma and retains cisplatin sensitivity, making it a standard model for ovarian cancer biology and chemotherapeutic response. This epithelial line exhibits dysregulated proliferation, migration, and apoptotic signaling. Its clinically relevant background allows examination of how dynactin disruption influences cancer cell behavior under platinum-based drug challenge, ensuring that phenotypes stem from ACTR1B loss rather than intrinsic drug resistance.
ACTR1B is an integral dynactin subunit that serves as an essential cofactor for cytoplasmic dynein. Through p150Glued (DCTN1) and p50/dynamitin (DCTN2), the dynactin complex links dynein heavy chain (DYNC1H1) to cargos and microtubules for minus-end-directed transport. ACTR1B directly interacts with these components, contributing to complex stability and cargo engagement. Upstream, mitotic kinases Aurora A and Plk1 phosphorylate dynactin to regulate dynein during mitosis. Downstream, ACTR1B-containing dynactin is critical for retrograde vesicular transport, mitotic spindle assembly, and Golgi organization. ACTR1B disruption thus impairs dynein-dependent processes, affecting trafficking and cell division.
In the A2780 model, ACTR1B knockout helps dissect dynactin-mediated transport roles in proliferation and drug response. Cisplatin sensitivity enables direct assessment of how trafficking defects alter chemotherapeutic efficacy. Given dynein-dynactin involvement in mitotic spindle integrity, this system allows investigation of mitotic defects contributing to chromosomal instability, an ovarian cancer hallmark. Additionally, dynactin-dependent Golgi organization and secretion pathways may modulate receptor presentation and tumor signaling, bridging basic cell biology with translational oncology.
These polyclonal ACTR1B knockout cells support diverse assays: immunoblotting and RT-qPCR for target validation, immunofluorescence for Golgi/mitotic spindle morphology, and live-cell imaging of organelle transport. Cell viability, apoptosis, and migration/invasion studies reveal roles in cancer fitness. The model is also suited for cisplatin sensitivity profiling and drug screening to identify dynactin-dynein pathway vulnerabilities. For additional information, contact Ascent Research.
